Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke.

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke.

Petri T. Kovanen, Alpo Vuorio, Markku Kaste

There is a continuing need for research about the underlying mechanisms behind ischemic strokes in COVID-19 patients. Pre-existing endothelial dysfunction, especially if it is accompanied by a viral infection of the endothelial cells may present an important mechanism behind the immunothrombotic/thromboembolic complications of the COVID-19 illness. Here we emphasize that pharmacotherapy with statins could partly counteract such pathophysiological scenarios. Accordingly, using familial hypercholesterolemia (FH) as a pertinent example of a lifelong endothelial dysfunction, we aim to make the clinicians and consulting neurologists aware of statins as a possible adjuvant therapy in the context of an increased risk of ischemic stroke in patients with COVID-19. Based on recent clinical evidence, there is a need to encourage clinicians and consulting neurologists to continue or initiate effective statin treatment to prevent an ischemic stroke, particularly when they encounter a hypercholesterolemic COVID-19 patient with FH.

2021

covid-19, Stroke, Endothelial dysfunction, Statins, Familial hypercholesterolemia, LDL cholesterol

10.1016/j.ensci.2021.100344

eNeurologicalSci